Provided by Tiger Trade Technology Pte. Ltd.

Nexalin Technology, Inc.

3.63
-0.4800-11.68%
Post-market: 3.750.1200+3.31%19:56 EDT
Volume:68.18K
Turnover:254.03K
Market Cap:3.81M
PE:-0.26
High:3.95
Open:3.95
Low:3.50
Close:4.11
52wk High:50.70
52wk Low:3.50
Shares:1.05M
Float Shares:844.70K
Volume Ratio:0.15
T/O Rate:8.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.8684
EPS(LYR):-15.0475
ROE:-240.25%
ROA:-119.22%
PB:2.50
PE(LYR):-0.24

Loading ...

Nexalin Technology - No Serious Adverse Events or Seizures Reported in Nexalin Trial

THOMSON REUTERS
·
Jun 10

Nexalin Technology - Reports 77.8% Anxiety Response Rate at End of Treatment

THOMSON REUTERS
·
Jun 10

Nexalin Technology - Overall Quality of Life Improves Significantly at End of Treatment

THOMSON REUTERS
·
Jun 10

Nexalin Technology - Completes 8-Week Clinical Trial of 15 Ma, 77.5 Hz Neurostimulation in Anxiety

THOMSON REUTERS
·
Jun 10

Nexalin Technology Wins US Patent Protecting Neurostimulation Method Through 2042

MT Newswires Live
·
Jun 04

Nexalin wins US patent for dynamic frequency brain stimulation targeting anxiety, depression, insomnia

Reuters
·
Jun 04

Maxim Group Reaffirms Their Buy Rating on Nexalin Technology, Inc. (NXL)

TIPRANKS
·
May 21

Nexalin closes acquisition of PONM digital health platform for USD 1.3 million

Reuters
·
May 19

Nexalin Acquires AI-Integrated Digital Health Platform Behind Halo™ Clarity and Nexalin Neurocare™ Ahead of Planned FDA Pivotal Trial

THOMSON REUTERS
·
May 19

Nexalin Q1 FY26 net loss widens 5% to $2.1 million; revenue drops 64% to $14,950

Reuters
·
May 09

Nexalin Technology Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
May 08

Nexalin study shows insomnia improvement with 15 mA, 77.5 Hz brain stimulation

Reuters
·
Apr 28

Morgan Stanley Sticks to Their Buy Rating for Nuix Ltd. (NXL)

TIPRANKS
·
Apr 27

Nuix Ltd. (NXL) Gets a Buy from RBC Capital

TIPRANKS
·
Apr 24

BRIEF-Nexalin Technology Advances Clinical Trial Of HALO Clarity Toward Q2 2026 Enrollment

Reuters
·
Apr 22

Nexalin Technology enters agreements to advance HALO Clarity trial

TIPRANKS
·
Apr 22

Nexalin Technology Advances Pivotal Clinical Trial of Halo™ Clarity Toward Q2 2026 Enrollment

THOMSON REUTERS
·
Apr 22

Nexalin Technology: Patient Enrollment Currently Expected to Begin in Q2 of 2026

THOMSON REUTERS
·
Apr 22

Nexalin targets Q2 2026 enrollment for pivotal HALO Clarity insomnia trial

Reuters
·
Apr 22

BUZZ-U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems

Reuters
·
Apr 16